Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis B 9Carcinoma, Hepatocellular 9Lymphoma, Non-Hodgkin 3Lymphoma 3Stomach Neoplasms 1Recurrence 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Liver Neoplasms 1Hepatitis B, Chronic 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Bevacizumab 14Cisplatin 12Surveys and Questionnaires 11Gemcitabine 9Drug Therapy 9Standard of Care 8Nivolumab 7Cetuximab 7pembrolizumab 6S 1 (combination) 6Cyclophosphamide 6atezolizumab 5Specimen Handling 5Endoscopic Mucosal Resection 5Educational Status 5Docetaxel 5Blood Specimen Collection 5fludarabine 4aldesleukin 4Radiotherapy 4Radiosurgery 4Pemetrexed 4IFL protocol 4Folfox protocol 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Neoplasms × entecavir × Clear all
NCT06966232 2025-05-11

Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers

Sun Yat-sen University

Phase 3 Recruiting
136 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡